Cellectis (NASDAQ:CLLS) Shares Pass Above Fifty Day Moving Average of $2.74

Cellectis S.A. (NASDAQ:CLLS) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $2.74 and traded as high as $2.75. Cellectis shares last traded at $2.65, with a volume of 44,068 shares changing hands.

Cellectis Price Performance

The company has a quick ratio of 2.20, a current ratio of 2.20 and a debt-to-equity ratio of 0.57. The company has a 50 day moving average of $2.74 and a two-hundred day moving average of $2.50. The firm has a market cap of $147.30 million, a P/E ratio of -1.59 and a beta of 3.13.

Institutional Investors Weigh In On Cellectis

Large investors have recently made changes to their positions in the company. Millennium Management LLC increased its holdings in Cellectis by 18.5% during the 4th quarter. Millennium Management LLC now owns 679,966 shares of the biotechnology company’s stock valued at $1,428,000 after purchasing an additional 106,125 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Cellectis by 166.5% during the first quarter. Jane Street Group LLC now owns 603,253 shares of the biotechnology company’s stock worth $2,789,000 after purchasing an additional 376,862 shares during the last quarter. State Street Corp increased its stake in shares of Cellectis by 3.4% in the third quarter. State Street Corp now owns 262,368 shares of the biotechnology company’s stock valued at $601,000 after buying an additional 8,643 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in Cellectis by 9.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 133,143 shares of the biotechnology company’s stock worth $410,000 after buying an additional 11,723 shares in the last quarter. Finally, CVI Holdings LLC bought a new stake in Cellectis during the 1st quarter worth about $250,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.